4D Molecular Therapeutics (FDMT) Liabilities and Shareholders Equity (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $512.9 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 0.55% year-over-year to $512.9 million in Q1 2026; TTM through Mar 2026 was $2.0 billion, a 14.04% decrease from a year earlier, with the FY2025 full-year figure at $566.7 million, up 1.13% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $512.9 million, down from $566.7 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for FDMT reached as high as $629.9 million in Q1 2024 and fell as low as $244.0 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $433.8 million across 5 years, with a median of $424.0 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity jumped 158.13% in 2024 and decreased 29.81% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $261.8 million in 2022, then rose by 29.81% to $339.9 million in 2023, then soared by 64.87% to $560.4 million in 2024, then grew by 1.13% to $566.7 million in 2025, then retreated by 9.49% to $512.9 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $512.9 million in Q1 2026, $566.7 million in Q4 2025, and $424.0 million in Q3 2025.